Abstract Details

Title Evaluation of Withdrawal Seizures During Conversion from Antiepileptic Drug Regimens Containing Carbamazepine to Eslicarbazepine Acetate Monotherapy

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 6-002

Objective To evaluate daily seizure frequency during conversion from baseline antiepileptic drug (AED) regimens containing carbamazepine (CBZ) to eslicarbazepine acetate (ESL) monotherapy, compared with conversion from AED regimens not containing CBZ.

Background Withdrawal seizures can occur when transitioning from CBZ to alternative AEDs, with the highest rate of withdrawal seizures within the first 2 weeks of stopping treatment with CBZ. ESL is a once-daily oral AED for focal (partial-onset) seizures.

Design/Methods Data were pooled from two Phase III randomized, dose-blind, conversion-to-ESL monotherapy trials (093-045 and -046) in adults (16-70 years) with focal seizures uncontrolled by 1–2 AEDs. Following an 8-week baseline period, eligible patients were randomized 2:1 to ESL 1600 mg or 1200 mg once daily for 18 weeks (2-week titration period, 6-week AED-taper/conversion period, 10-week monotherapy period). We evaluated daily seizure frequency during the AED-taper/conversion period in patients who converted from a treatment regimen including CBZ (+CBZ, ESL 1600 mg or 1200 mg) compared with those who converted from a regimen that did not include CBZ (−CBZ, ESL 1600 mg or 1200 mg).

Results The analysis population included 332 patients (+CBZ ESL 1600 mg, n = 52; +CBZ ESL 1200 mg, n = 37; –CBZ ESL 1600 mg, n = 162; –CBZ ESL 1200 mg, n = 77). During the baseline AED-taper period, there was no difference in daily seizure frequency between the four treatment groups.

Conclusions

Although withdrawal seizures can occur when converting from CBZ to other AEDs, during two conversion-to-ESL-monotherapy clinical trials, seizure frequency did not appear to differ between patients who tapered from AED regimens containing CBZ versus those who did not.

Authors/Disclosures
PRESENTER	No disclosure on file
Todd Grinnell, PhD	Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Uma Menon, MD, MBA, FAAN, FAAN (HMH JFK Neuroscience Institute)	Dr. Menon has nothing to disclose.
David E. Blum, MD	Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics.
	No disclosure on file

��ɫ��

��ɫ��